Drugs / SHR4640
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT06196580 | Jan → Feb 2024 | gout | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05954169 | Aug 2023 → Jul 2024 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04850638 | Jun → Sep 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04620408 | Dec 2020 → Jan 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04586803 | Oct → Nov 2020 | gout | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04305392 | Aug 2020 → Dec 2022 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04260373 | Mar → Apr 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04157959 | Oct 2019 → Jun 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03211403 | Jul 2017 → Feb 2018 | gout | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03131583 | Feb 2017 → Jan 2018 | gout | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03015948 | Sep → Nov 2016 | gout | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02890966 | Jul 2016 → Feb 2017 | gout | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02815839 | Nov 2015 → Feb 2017 | gout | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07362355 | Feb 2026 → Jul 2027 expected | gout | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05513976 | Sep 2022 → May 2023 | gout | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04180982 | Dec 2019 → Jul 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03185793 | Jul 2017 → Jul 2018 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04956432 | Jun 2021 → Dec 2023 | gout | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04052932 | Jul 2019 → Jul 2021 | gout | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR4640 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04620408 ↗ |
| Known as | Ruzinurad | ChEMBL registry synonym — accepted as the source's own label CHEMBL3746329 ↗ |
| Action | Inhibit | “a highly selective urate transporter 1 inhibitor” PMID 33693494 ↗ Nov 20211“Solute carrier family 22 member 12 inhibitor” CHEMBL3746329 ↗ |
| Modality | Small molecule | — CHEMBL3746329 ↗ |
| Route | Oral | “oral administration” NCT02890966 ↗ |
| Target | SLC22A12 | “Solute carrier family 22 member 12 inhibitor” CHEMBL3746329 ↗ |